Skip to main content
Premium Trial:

Request an Annual Quote

Signal Genetics Lab Nabs CAP Accreditation

NEW YORK (GenomeWeb) – Signal Genetics today announced that the College of American Pathologists has awarded accreditations to the firm's Little Rock, Ark.-based laboratory.

"This further demonstrates our company's dedication to providing a quality diagnostic to patients suffering from multiple myeloma, and the physicians who treat them, in order to improve individual care," Signal CEO Sam Riccitelli said in a statement.

Carlsbad, Calif.-based Signal Genetics provides oncology molecular diagnostic services, offering the MyPRS microarray gene expression profiling assay for multiple myeloma. In February, the firm closed a $9 million public offering.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.